'); } else { var query = elem.find('.keywords').html(); $.ajax({ context: elem, url: 'https://wn.com/api/upge/cheetah-search-adv/video', cache: true, data: { 'query': query }, dataType: 'jsonp', success: function(text) { if (text.length > 0) { video_id = text[0].id; elem.find('.player').html(''); } } }); } } var stopAllYouTubeVideos = function() { var iframes = document.querySelectorAll('iframe'); Array.prototype.forEach.call(iframes, function(iframe) { iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*'); }); } jQuery(function() { jQuery(".playVideo").live("click", function() { if(!$(this).hasClass("played")){ stopAllYouTubeVideos(); var elem = $(this); setTimeout(function(){ mouseOverMe(elem); }, 1000); } }); jQuery(".description_box .expandContent").live("click", function() { elem = $(this).parent().parent().parent().find('.descContent'); if(elem.height() > 51) { elem.css('height', '44px'); $(this).html('Show More '); }else{ elem.css('height', 'auto'); $(this).html('Hide '); } }); jQuery('.interview-play-off').click(function() { $(".interview-play-off").hide(); $(".interview-play").show(); $(".videoplayer-control-pause").click(); }); jQuery(".video-desc .show_author_videos").live("click", function() { query = $(this).attr('title'); container = $(this).parent().parent().parent().find('.video-author-thumbs'); $(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px'); jQuery.ajax({ url: '/api/upge/cheetah-photo-search/videoresults', data: {'query': query}, success: function(text) { if(!text) { text = i18n("No results"); } container.html(jQuery(text)); } }); }); }); // -->

Latest News for: egfr

Edit

Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy (Summit Therapeutics Inc)

Public Technologies 27 Mar 2026
Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi ... on EGFR-TKIs3,4 ... EGFR sensitizing mutation+. Progressed on 3rd gen EGFR-TKI ... Prior EGFR-TKI ... EGFR Mutation.
Edit

EGFR Non Small Cell Lung Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials ...

GetNews 24 Mar 2026
EGFR Non Small Cell Lung Cancer Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the EGFR Non Small Cell Lung Cancer Market.
Edit

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

PR Newswire 24 Mar 2026
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations. Safety and tolerability findings included ... No treatment discontinuations due to adverse events ... (NASDAQ ... S ... .
Edit

EGFR + NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for ...

GetNews 23 Mar 2026
Inactive Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs ...
Edit

Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

PR Newswire 21 Mar 2026
The findings suggest that ZEGFROVY monotherapy has the potential to become the first and only chemo free, oral agent to treat newly diagnosed NSCLC patients with EGFR exon20ins ... for the treatment of relapsed or refractory NSCLC with EGFR exon20ins.
Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Nasdaq Globe Newswire 04 Mar 2026
Second clinical candidate from HUTCHMED’s next-generation ATTC platform — ... .
Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with

The Eagle-Tribune 04 Mar 2026
Second clinical candidate from HUTCHMED’s next-generation ATTC platform — ... .
Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors (Form 6-K) (HUTCHMED (China) Ltd)

Public Technologies 04 Mar 2026
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors ... - Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling -.
Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Pharmiweb 04 Mar 2026
— Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — ... EGFR is highly expressed in multiple types of solid tumors and is well recognized as a driving force in tumorigenesis and disease progression.
Edit

Understanding eGFR Levels and How Ayurveda Helps Maintain Kidney Health

GetNews 27 Feb 2026
One of the most important indicators of kidney function is the Estimated Glomerular Filtration Rate (eGFR). Understanding your eGFR levels can help you take timely steps to protect and support your kidney health ... Normal eGFR Range and What It Means.
Edit

Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

Pharmiweb 24 Feb 2026
The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.17  Among the most common driver mutations in NSCLC are alterations in EGFR, which is a ...
×